Ep. 389 - IgA nephropathy, Overton hearing, reverse mergers' new look
This BioCentury podcast episode covers three major topics: the rapid advancement of IgA nephropathy drug development driven by academic discovery and FDA guidance, FDA Commissioner nominee Heidi Overton's confirmation hearing where she emphasized speed and vaccine safety, and the growing popularity of reverse mergers with concurrent PIPE financing as an alternative to traditional IPOs for biotech companies.
Summary
The episode opens with discussion of IgA nephropathy, a rare kidney disease that has shifted from neglected status to a major drug development priority. Lauren Martz explains that seven drugs have been approved globally for this indication in the past five years, compared to none before, driven by academic innovations in biomarkers and FDA's flexible regulatory approach. Three therapeutic categories exist: kidney-protective drugs, complement inhibitors that reduce inflammation, and upstream APRIL/BAF inhibitors that prevent the abnormal antibody cascade. Companies including Climb Bio, Jade Biosciences, Boulevard, Vertex, Takeda, and Biogen are competing in this space. Key differentiators for next-generation therapies include longer dosing intervals and improved safety profiles. Challenges ahead include establishing clinical trial designs with new standards of care and managing placebo-controlled trial requirements despite existing approved therapies.
Steve Usden discusses FDA Commissioner nominee Heidi Overton's HELP Committee confirmation hearing. Overton's prepared remarks emphasized Trump's directive to "go fast" and endorsed Operation Trial Blazer for accelerating early-stage development. Unusually, she began by thanking Jesus Christ and citing biblical life verses. Unlike predecessor Marty McCary, she praised FDA staff, unambiguously supported vaccine safety and efficacy, and stated that all FDA-approved products should be respected. However, her refusal to explicitly state Trump was wrong on public health issues disappointed Democrats, while Republican Josh Hawley and some Democrats questioned whether she would resist pressure from Trump and HHS Secretary Kennedy. The critical vote may hinge on chairman Bill Cassidy's belief that she will follow through on her statements, particularly regarding vaccines and the abortion drug mifepristone, where she refused to prejudge an ongoing safety review despite Hawley's contrary position.
Regarding tariffs, Usden reports that the Trump administration released sparse guidance on exemptions, establishing only an email submission process without clear timelines or appeals mechanisms. Many biotech companies importing products from China, Australia, and Canada face uncertainty and increased compliance costs. Paul Bananos then discusses the surge in reverse mergers with concurrent PIPE (private investment in public equity) financing as an IPO alternative. Unlike historical reverse mergers motivated by accessing shell company cash, these modern deals feature substantial investor syndicates—often in nine-figure ranges—that function similarly to crossover rounds. Benefits for companies include pricing certainty and regulatory flexibility, while investor syndicates gain control over their investor mix and access to specialized biotech knowledge. Examples include North Immunology and several Asia-based new companies. Wedbush Securities has led approximately 15 such deals in 2026, nearly matching the IPO count and signaling healthy capital deployment in biotech. Finally, the episode briefly mentions Merck's $400 million upfront acquisition of a preclinical KRAS G12D inhibitor from Shanghai Sipuri Pharmaceutical ($2 billion+ total deal value) and the launch of LinkCell, a next-generation CAR-T company with renal cell carcinoma program in the clinic and executive talent from Cystimmune and Bristol-Myers Squibb.
About this episode
Seven global approvals in five years, validated biomarkers and FDA flexibility have turned IgA nephropathy from a neglected rare disease into a crowded field, with Biogen, Novartis, Takeda, Climb Bio and Jade chasing targets such as APRIL, BAFF and CD38. On the latest BioCentury This Week podcast, BioCentury's analysts assess how next-generation therapies are competing on safety and longer dosing intervals. The analysts also discuss Heidi Overton's FDA commissioner confirmation hearing and li...
Key Insights
- Seven IgA nephropathy drugs have been approved globally in five years through convergence of academic biomarker discovery, FDA regulatory agility, and identification of three distinct therapeutic intervention points in the disease pathway, compared to zero approvals before this period.
- Heidi Overton's confirmation testimony prioritized speed in drug development and explicitly endorsed all FDA-approved vaccines and products as safe and effective, contrasting sharply with her predecessor Marty McCary's criticism of FDA staff and his defense of Secretary Kennedy's unscientific health recommendations.
- The critical question determining Overton's confirmation vote is whether committee chairman Bill Cassidy believes she will resist pressure from Trump and Kennedy to overturn regulatory decisions, given Kennedy's prior broken promises to Cassidy about vaccine positions.
- The Trump administration's tariff exemption guidance relies on undefined case-by-case Commerce Department decisions with no specified appeals process, creating substantial compliance uncertainty and increased costs for biotech companies importing from non-exempt countries like China, Australia, and Canada.
- Modern reverse merger deals with concurrent PIPE financing function distinctly from historical reverse mergers by featuring nine-figure investor syndicates that act like crossover rounds, providing pricing certainty and investor selectivity while companies receive regulatory flexibility and clean shells through dividend distributions or program outlicensing.
- Investor syndicates in reverse merger deals with PIPEs specifically value control over their investor composition to ensure biotech-specialized participants who better understand complex therapeutic stories, rather than accepting the generalist and mutual fund allocations typical in IPO underwriting.
- Next-generation IgA nephropathy therapies are differentiating primarily through extended dosing intervals and improved safety profiles, with anti-CD38 approaches potentially enabling six-month treatment followed by 18 months off-therapy, particularly benefiting women of childbearing age.
- Reverse mergers rebounded from a low of seven deals in 2025 to approximately 15 or more in 2026, with concurrent PIPE funding representing recycled capital from M&A deal proceeds being redeployed into forward-moving biotech programs as a signal of sector health.
Topics
Transcript
Everything has fallen into place to shift IgA nephropathy from a neglected rare disease to a drug development priority. Among biopharma companies with larger companies such as Biogen, Novartis, Takeda, and Chemed, and smaller companies such as Climb Bio and Jade chasing targets like april bath and cd38 on the latest biosentry this week podcast we check in on the state of play in iga nephropathy plus we check in on two stories we touched on last week what went down at the confirmation hearing for FDA Commissioner nominee Heidi Overton? And reverse mergers. How the financing vehicle went from uncool to sexy IPO alternative. We get the scoop from our news editor and venture writer, Paul Bananos, also joining…
Full transcript available for MurmurCast members
Sign Up to AccessMore from BioCentury This Week
Ep. 390 - Live from Amsterdam: Grand Rounds Europe takeaways
BioCentury's Grand Rounds Europe conference in Amsterdam gathered biotech leaders to discuss emerging therapeutic mechanisms, the role of fundamental biology in drug discovery, and the importance of entrepreneurship in European biotech. Key themes included the potential of GLP-1 successors, aging biology, the risks of over-complex molecular constructs, and the need for hypothesis-driven science over permutation testing.
Ep. 388 - Biotech IPOs, CAR T safety & pharma tariffs
Episode 388 covers three major biotech topics: Electra's biotech IPO upsized but fell 12% on its first trading day, marking an end to a winning streak; fatal toxicities in Novartis' autoimmune CAR-T trial raise safety concerns across the sector; and pharma tariffs set for September 29th lack clear implementation guidance, disproportionately affecting small and mid-sized companies.
Ep. 387 - Psychedelics at FDA, Mike Davis’ CDER & tRNAs
Novartis experienced three major clinical trial failures in one week, wiping out $40 billion in market cap, with the most significant being the failed Phase 3 for Pellicarson (anti-LP(a) antisense therapy). The episode discusses potential explanations for the failure and broader implications for RNA therapeutics and cardiovascular drug development, while also covering pharma M&A trends showing increased focus on disruptive technologies and rising China biotech partnerships.
Ep. 386 - Novartis misses, pharma deals analysis, MFN carve-outs
Novartis suffered three major clinical trial failures in one week, losing $40 billion in market cap, particularly from the failed LP(a)-targeting antisense therapy Pelacarsen, raising questions about the molecule, target, and timing of intervention. Pharma companies are increasingly embracing disruptive technologies like bispecifics, in vivo CAR-Ts, and siRNAs through licensing deals and M&A, with Eli Lilly leading dealmaking activity; meanwhile, the Trump administration is pressuring mid-tier U.S. biotechs to sign Most Favored Nation drug pricing agreements with unclear terms.
Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton
This BioCentury podcast episode covers three major healthcare policy developments: the Trump administration's Most Favored Nation (MFN) drug pricing deals with 17 pharmaceutical companies, Eli Lilly's $2.9 billion acquisition of Merida for autoimmune disease therapeutics, and the nomination of Heidi Overton as FDA commissioner, alongside RevMed's rapid FDA approval for a pancreatic cancer therapy.